Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
19 October 2022 - 1:30AM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announces its sponsorship of the Fall
Clinical Dermatology Conference, being held October 20-23 in Las
Vegas. As a Gold Industry Sponsor, Biofrontera will host an exhibit
booth showcasing commercial and upcoming products, an Advisory
Board meeting featuring leading dermatologists and four posters on
investigator-initiated and Company-sponsored research with Ameluz®.
The Biofrontera booth will feature educational
and commercial information on its flagship drug Ameluz®
(aminolevulinic acid hydrochloride) topical gel, 10%, used in
combination with the RhodoLED® lamp series for photodynamic therapy
(PDT) of actinic keratosis (AK), and its topical antibiotic Xepi®
(ozenoxacin cream, 1%), for the treatment of impetigo. The booth
will also showcase both the BF-RhodoLED® as well as Biofrontera’s
new larger PDT lamp, RhodoLED® XL, which are approved for use in
combination with Ameluz for the treatment of mild and moderate AK
on the face and scalp.
Additionally, Biofrontera is sponsoring an
Advisory Board meeting on Friday, October 21st. The meeting will
consist of two sessions providing advanced education on the
advantages and current landscape of photodynamic therapy and
sharing real-world PDT utilization experiences amongst PDT experts
and industry leading dermatologists.
The following posters will be available for
viewing in the exhibit hall:
1.
Title: Lesion Clearance Rate After Red-Light
Photodynamic Therapy with 10% Aminolevulinic Acid Gel in Relation
to the Epidermal Extent of Atypical Keratinocytes in Actinic
Keratosis – Retrospective Exploratory Analysis of Three Pivotal
Phase III TrialsExploratory data analysis from three Phase
III studies sponsored by Biofrontera Biosciences GmbHAuthors:
Erhard Bierhoff, Joel L. Cohen, Rolf-Markus Szeimies, Uwe Reinhold,
Thomas Dirschka
2. Title:
Field Therapy for Actinic Keratosis: Structured Review of
the Literature on Efficacy, Cost, and AdherenceThis study
was investigator-initiated and funded by Biofrontera Inc.Authors:
Nathaniel Lampley III, Rachel Rigo, Todd Schlesinger, Anthony M.
Rossi
3.
Title: Long-Term Follow Up of ALA 10% Gel and
Red-Light Photodynamic Therapy for the Treatment of Squamous Cell
Carcinoma in SituThis study was
investigator-initiated and funded by Biofrontera Inc.Authors: Paul
Shim, Nathalie Zeitouni
4. Title:
Photodynamic Therapy for Facial Actinic Keratosis with
Aminolevulinic Acid 10% Gel,
Microneedling, and Red-Light
IlluminationThis study was investigator-initiated and
funded by Biofrontera Inc. Authors: Ziv Schwartz, Gary
Goldenberg
“At this year’s Fall Clinical conference we will
spotlight the hard work by our clinical and commercial teams
throughout 2022, along with studies by independent investigators
that further the body of knowledge on PDT. We look forward to
meeting with industry leaders and clinicians through a variety of
formats ranging from poster presentations to Advisory Board
sessions,” said Erica Monaco, Chief Executive Officer of
Biofrontera Inc. “We also look forward to showcasing our new,
larger RhodoLED® XL PDT lamp, which is among the latest
breakthroughs in medical dermatology and aesthetics, allowing for
the illumination of a larger surface
area, thereby enabling simultaneous treatment of AK
lesions that are distant from one another.”
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024